Preoperative and Postoperative Systemic Therapy for Operable Non–Small-Cell Lung Cancer

Jamie E. Chaft, Yu Shyr, Boris Sepesi, Patrick M. Forde

研究成果: Review article同行評審

9 引文 斯高帕斯(Scopus)


Cisplatin-based adjuvant chemotherapy remains the standard of care for patients with resected stage II or III non–small-cell lung cancer. However, biomarker-informed clinical trials are starting to push the management of early-stage lung cancer beyond cytotoxic chemotherapy. This review explores recent and ongoing studies focused on improving cytotoxic chemotherapy and incorporating targeted and immunotherapies in the management of early-stage, resectable lung cancer. Adjuvant osimertinib for patients with EGFR-mutant tumors, preoperative chemoimmunotherapy, and adjuvant immunotherapy could improve outcomes for selected patients with resectable lung cancer, and ongoing or planned studies leveraging biomarkers, immunotherapy, and targeted therapy may further improve survival. We also discuss the unique barriers associated with clinical trials of early-stage lung cancer and the need for innovative trial designs to overcome these challenges.

頁(從 - 到)546-555
期刊Journal of Clinical Oncology
出版狀態Published - 2022 2月 20

All Science Journal Classification (ASJC) codes

  • 腫瘤科
  • 癌症研究


深入研究「Preoperative and Postoperative Systemic Therapy for Operable Non–Small-Cell Lung Cancer」主題。共同形成了獨特的指紋。